Healthcare Industry News: Bristol-Myers Squibb
News Release - February 29, 2008
Tercica Announces Changes to Its Board of Directors and Management TeamBRISBANE, Calif.--(HSMN NewsFeed)--Tercica, Inc. (NASDAQ:TRCA ) today announced that it has named Richard King as President and Chief Operating Officer. Previously, Mr. King was Tercica’s Chief Operating Officer. John A. Scarlett, M.D., will remain as the Chief Executive Officer of Tercica. The Company also announced that Ajay Bansal has been named Executive Vice President and Chief Financial Officer. Mr. Bansal was previously Tercica’s Senior Vice President and Chief Financial Officer.
In addition, the Company also announced that Faheem Hasnain has joined the Company’s board of directors, and that Dennis Henner has resigned from the board, effective immediately.
Mr. King joined Tercica in February 2007 as its Chief Operating Officer. Prior to joining Tercica, he served as Executive Vice President, Commercial Operations of Kos Pharmaceuticals, Inc. from 2002 to 2006. At Kos, he was responsible for sales, marketing, managed care, sales operations and customer service functions. From 2000 to 2002, Mr. King was Senior Vice President of Commercial Operations at Solvay Pharmaceuticals, and from 1992 to 2000, held various marketing positions at SmithKline Beecham Pharmaceuticals.
Mr. Hasnain is currently the Executive Vice President, Oncology Rheumatology Strategic Business Unit at Biogen Idec, Inc., and has served in that position since October 2007. Prior to that, Mr. Hasnain had served as Biogen Idec’s Senior Vice President, Oncology Rheumatology Strategic Business Unit since February 2007 and as its Senior Vice President, Oncology Strategic Business Unit from October 2004. Before joining Biogen Idec, he served as President, Oncology Therapeutics Network at Bristol-Myers Squibb from March 2002 to September 2004. From January 2001 to February 2002, Mr. Hasnain served as Vice President, Global eBusiness at GlaxoSmithKline, and prior to 2000, he served in key commercial and entrepreneurial roles within GlaxoSmithKline and its predecessor organizations, spanning global eBusiness, international commercial operations, sales and marketing.
“Since joining Tercica, Richard has been instrumental in developing our commercial organization and crafting our overall business strategy. We are confident that, as President and Chief Operating Officer, he will successfully lead Tercica’s key business operations in the years ahead,” said Chief Executive Officer of Tercica, John A. Scarlett, M.D. "Faheem joins the board of Tercica as an accomplished strategist and business leader in the biotech industry, and adds valuable depth to our board of directors with his extensive commercial experience," continued Dr. Scarlett.
Tercica is a biopharmaceutical company committed to improving endocrine health by partnering with the endocrine community to develop and commercialize new therapeutics for pediatric and adult growth disorders, and for adult metabolic disorders. For further information on Tercica, please visit www.tercica.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.